Paper Details

  1. Home
  2. Paper Details

The Evidence for Sparsentan-Mediated Inhibition of <i>I</i><sub>Na</sub> and <i>I</i><sub>K(erg)</sub>: Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a Receptor.

Author: ChoHsin-Yen, ChuangTzu-Hsien, WuSheng-Nan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Sparsentan, a dual antagonist of endothelin type A and angiotensin II receptors, has shown potential in treating focal segmental glomerulosclerosis. This study examined the effects of sparsentan on ionic currents in pituitary GH3 somatolactotrophs. The study found that sparsentan differentially inhibited the peak and late components of voltage-gated Na+ current and inhibited K+ currents.
Paper Details　
Original Abstract of the Article :
Sparsentan is viewed as a dual antagonist of endothelin type A (ET<sub>A</sub>) receptor and angiotensin II (AngII) receptor and it could be beneficial in patients with focal segmental glomerulosclerosis. Moreover, it could improve glomerular filtration rate and augment protective tissue remodeling ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773265/

データ提供：米国国立医学図書館（NLM）

Sparsentan: A Multifaceted Drug with Unidentified Ionic Actions

This study investigates the effects of sparsentan, a dual antagonist of endothelin type A (ETA) receptor and angiotensin II (AngII) receptor, on ionic currents in pituitary GH3 somatolactotrophs. The authors found that sparsentan differentially inhibited voltage-gated Na+ current (INa) and erg-mediated K+ current, suggesting a potential impact on neuronal excitability. This research highlights the complex and potentially unidentified ionic mechanisms underlying the pharmacological actions of sparsentan.

Beyond Receptor Antagonism: A Deeper Look at Sparsentan's Actions

This study expands our understanding of sparsentan's pharmacological profile, revealing potential effects on ionic currents that are not directly related to its antagonism of ETA and AngII receptors. These findings suggest a more complex mechanism of action for this promising drug.

Unraveling the Mysteries of Sparsentan: A Quest for Understanding

This research opens new avenues for exploring the mechanisms of action of sparsentan. The authors' findings suggest the need for further investigation into the potential effects of this drug on ionic currents, particularly in the context of its therapeutic applications.

Dr. Camel's Conclusion

This study takes us on a journey into the intricate world of ionic currents, revealing the complex and multifaceted nature of sparsentan's actions. It's like a hidden oasis in the desert of pharmacological research, promising new insights and potentially valuable therapeutic applications.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-01-28
Further Info :

Pubmed ID

35052766

DOI: Digital Object Identifier

PMC8773265

Related Literature

Article Analysis
・Effects of sparsentan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.